SuppreMol: Baxter acquires autoimmune play SuppreMol

Baxter International Inc. (NYSE:BAX) acquired SuppreMol GmbH (Martinsried, Germany) for EUR 200 million ($223.9 million).SuppreMol's lead compound is SM101, a recombinant, soluble, non-glycosylated version of Fc gamma receptor IIb (CD32B; FCGR2B) that has completed Phase IIa trials to treat idiopathic thrombocytopenic purpura (ITP) and systemic lupus erythematosus (SLE). Baxter intends to begin Phase III studies by 2017.